What the guidelines say

The British HIV Association recommends that mild lipoatrophy associated with AZT or d4T treatment should be managed by switching from those drugs to abacavir or tenofovir.

In more obvious cases of facial fat loss, or where d4T or AZT cannot be switched, polylactic acid injections should be given to correct the fat loss.

In severe cases Bio-Alcamid may be more effective than polylactic acid.

Funding in the UK for these treatments varies according to district. Clinics that do not offer polylactic acid injections may be able to refer patients to hospitals with experience of treating patients with facial fat loss.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.